Wedbush Securities’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $490K | Buy |
634
+1
| +0.2% | +$766 | 0.01% | 686 |
|
|
2025
Q4 | $489K | Sell |
633
-215
| -25% | -$146K | 0.01% | 689 |
|
|
2025
Q3 | $477K | Sell |
848
-46
| -5% | -$26K | 0.02% | 670 |
|
|
2025
Q2 | $469K | Buy |
894
+23
| +3% | +$12.8K | 0.02% | 652 |
|
|
2025
Q1 | $552K | Buy |
871
+28
| +3% | +$19.3K | 0.02% | 579 |
|
|
2024
Q4 | $600K | Buy |
843
+54
| +7% | +$45.3K | 0.02% | 545 |
|
|
2024
Q3 | $829K | Buy |
789
+121
| +18% | +$135K | 0.03% | 431 |
|
|
2024
Q2 | $702K | Sell |
668
-28
| -4% | -$27.1K | 0.03% | 486 |
|
|
2024
Q1 | $670K | Buy |
696
+102
| +17% | +$97K | 0.03% | 528 |
|
|
2023
Q4 | $522K | Sell |
594
-7
| -1% | -$5.76K | 0.02% | 544 |
|
|
2023
Q3 | $495K | Sell |
601
-55
| -8% | -$43.2K | 0.02% | 529 |
|
|
2023
Q2 | $471K | Buy |
656
+38
| +6% | +$29.3K | 0.02% | 564 |
|
|
2023
Q1 | $508K | Buy |
618
+67
| +12% | +$50.5K | 0.03% | 522 |
|
|
2022
Q4 | $398K | Sell |
551
-73
| -12% | -$53.9K | 0.02% | 601 |
|
|
2022
Q3 | $430K | Sell |
624
-117
| -16% | -$73.6K | 0.02% | 565 |
|
|
2022
Q2 | $438K | Sell |
741
-93
| -11% | -$60.5K | 0.02% | 581 |
|
|
2022
Q1 | $582K | Sell |
834
-36
| -4% | -$22.8K | 0.03% | 523 |
|
|
2021
Q4 | $549K | Buy |
870
+238
| +38% | +$146K | 0.02% | 583 |
|
|
2021
Q3 | $382K | Sell |
632
-9
| -1% | -$5.59K | 0.02% | 738 |
|
|
2021
Q2 | $358K | Sell |
641
-160
| -20% | -$81.1K | 0.02% | 778 |
|
|
2021
Q1 | $379K | Sell |
801
-541
| -40% | -$263K | 0.02% | 686 |
|
|
2020
Q4 | $648K | Buy |
1,342
+250
| +23% | +$135K | 0.06% | 377 |
|
|
2020
Q3 | $611K | Buy |
1,092
+24
| +2% | +$14.6K | 0.06% | 361 |
|
|
2020
Q2 | $666K | Buy |
1,068
+563
| +111% | +$320K | 0.06% | 321 |
|
|
2020
Q1 | $247K | Buy |
+505
| New | +$208K | 0.03% | 601 |
|
|
2015
Q4 | – | Sell |
-642
| Closed | -$299K | – | 767 |
|
|
2015
Q3 | $299K | Sell |
642
-835
| -57% | -$448K | 0.06% | 374 |
|
|
2015
Q2 | $753K | Sell |
1,477
-19
| -1% | -$9.27K | 0.14% | 176 |
|
|
2015
Q1 | $675K | Sell |
1,496
-64
| -4% | -$27.1K | 0.11% | 201 |
|
|
2014
Q4 | $640K | Sell |
1,560
-975
| -38% | -$383K | 0.1% | 203 |
|
|
2014
Q3 | $914K | Sell |
2,535
-50
| -2% | -$16.8K | 0.14% | 141 |
|
|
2014
Q2 | $730K | Buy |
+2,585
| New | +$766K | 0.12% | 184 |
|
Other funds holding REGN
VCM
N
Wedbush Securities's REGN Position: Q1 2026 in Review
Wedbush Securities increased its Regeneron Pharmaceuticals (REGN) stake by 0.16% in Q1 2026, buying an estimated $766 and bringing the position to 634 shares worth $490K. The position accounts for 0.01% of the portfolio, ranked #686.
Wedbush Securities first reported a position in REGN in Q2 2014 and has held it in 31 quarters since. The position peaked at $914K in Q3 2014. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Wedbush Securities held 634 shares of Regeneron Pharmaceuticals worth $490K as of Q1 2026.
- Wedbush Securities bought 1 Regeneron Pharmaceuticals share in Q1 2026, an estimated $766.
- Regeneron Pharmaceuticals made up 0.01% of Wedbush Securities's portfolio in Q1 2026, its #686 holding.
- Wedbush Securities first reported a position in Regeneron Pharmaceuticals in Q2 2014 and has held it in 31 quarters since.
- Wedbush Securities's Regeneron Pharmaceuticals position peaked at $914K in Q3 2014.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Wedbush Securities's 13F filing for Q1 2026, filed 21 Apr 2026.